The Journal of Immunology, Vol 146, Issue 7 2214-2219, Copyright © 1991 by American Association of Immunologists

ARTICLES

Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals

M Clerici, DR Lucey, RA Zajac, RN Boswell, HM Gebel, H Takahashi, JA Berzofsky and GM Shearer
Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Four synthetic peptides corresponding to the IIIB sequence of gp160 of HIV were recently reported to stimulate Th cell function by PBL from HIV-infected, asymptomatic patients. In the present report, we used these same peptides to demonstrate CTL activity in a similar patient population. EBV-transformed B-cell lines from asymptomatic, HIV seropositive and seronegative control donors were pre-incubated with the peptides. Fresh PBL from 19 (76%) of 25 HIV seropositive donors lysed autologous targets pulsed with at least one of the four peptides. Autologous targets pulsed with two non-immunogenic peptides were not lysed. PBL from none of the eight HIV seronegative controls lysed peptide-preincubated autologous targets. The CTL activity was mediated by T cells, was predominantly MHC class I restricted, and was increased by in vitro restimulation of PBL with the peptides. HLA A-2 was identified as a restricting element for all four peptides in different patients, and for three of the peptides in the same donor. HLA-A1 or - B8 may also present some of the peptides. Thus, the same peptides can be recognized by human Th cells and class I MHC-restricted CTL.

This article has been cited by other articles:

				Y. Nakagawa, H. Kikuchi, and H. Takahashi Molecular Analysis of TCR and Peptide/MHC Interaction Using P18-I10-Derived Peptides with a Single D-Amino Acid Substitution Biophys. J., April 1, 2007; 92(7): 2570 - 2582. [Abstract] [Full Text] [PDF]

				D. V. Havlir, M. C. Strain, M. Clerici, C. Ignacio, D. Trabattoni, P. Ferrante, and J. K. Wong Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years J. Virol., October 15, 2003; 77(20): 11212 - 11219. [Abstract] [Full Text] [PDF]

				L. A. Pinto, S. Sharpe, D. I. Cohen, and G. M. Shearer Alloantigen-Stimulated Anti-HIV Activity Blood, November 1, 1998; 92(9): 3346 - 3354. [Abstract] [Full Text] [PDF]

				P. Klenerman, R. E. Phillips, C. R. Rinaldo, L. M. Wahl, G. Ogg, R. M. May, A. J. McMichael, and M. A. Nowak Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection PNAS, December 24, 1996; 93(26): 15323 - 15328. [Abstract] [Full Text] [PDF]

				R. M. Blaese, K. W. Culver, A. D. Miller, C. S. Carter, T. Fleisher, M. Clerici, G. Shearer, L. Chang, Y. Chiang, P. Tolstoshev, et al. T Lymphocyte-Directed Gene Therapy for ADA- SCID: Initial Trial Results After 4 Years Science, October 20, 1995; 270(5235): 475 - 480. [Abstract] [PDF]

				H Takahashi, Y Nakagawa, C. Pendleton, R. Houghten, K Yokomuro, R. Germain, and J. Berzofsky Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant Science, January 17, 1992; 255(5042): 333 - 336. [Abstract] [PDF]